Company Description
OptMed is a clinical-stage medical device company focused on the development and commercialization of novel surgical adhesives for the localized treatment of patients with external and internal wounds.
Our proprietary technology platform is based on a chemistry called methylidene malonate (“MM212”), a biocompatible polymer originally designed for drug delivery which has been extensively tested for biocompatibility and adhesive properties in topical and internal applications.
MM212-based surgical adhesives have unique versatile properties which include strong bonding properties, the ability to bond to tissues in wet environments, elastic properties and biocompatibility with human tissues.
Our initial product candidates, BondEase® Topical Skin Adhesive and TearRepair Liquid Skin Protectant, are biocompatible tissue adhesives for topical applications.
BondEase was designed as a topical adhesive for the closure of acute incision and laceration wounds and TearRepair was designed as a topical skin protectant for fragile and damaged skin, such as for skin tears of the elderly.
We anticipate that we will file a new application with the FDA to obtain clearance to market BondEase and TearRepair in the United States within three months of the completion of this offering.
We are also at the early stage of development of our adhesive platform for two additional clinical indications to protect chronic wounds and to seal internal wounds and organ leakage.
| Country | United States |
| Founded | 2007 |
| Industry | Health Care |
| Sector | Health Care Equipment & Supplies |
| Employees | 4 |
| CEO | Ervin Braun |
Contact Details
Address: 745 Fifth Avenue, Suite 500 New York, NY 10151 United States | |
| Phone | (646) 898-2004 |
| Website | optmed.com |
Stock Details
| Ticker Symbol | OMED |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001469988 |
| Employer ID | 20-8866142 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ervin Braun | Chief Executive Officer and Director |
| Alain Klapholz | Chief Operating Officer, Chief Financial Officer, and Founder |
| Martin Sands | Director, Co-Chairman of the Board |
| Steven Sands | Director, Co-Chairman of the Board |
| Ruiping Dong, M.D., Ph.D. | Director |
| Kenneth Burhop, Ph.D | Director |
| Curtis L. Cetrulo, Jr., M.D., FACS, FAAP | Director |
| James J. Chao, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2023 | RW | Filing |
| Jul 26, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 15, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 11, 2022 | DRS | [Cover] Draft Registration Statement |
| Aug 11, 2015 | D | Notice of Exempt Offering of Securities |
| Mar 17, 2015 | D | Notice of Exempt Offering of Securities |
| Jun 27, 2014 | D | Notice of Exempt Offering of Securities |
| Jun 11, 2013 | D | Notice of Exempt Offering of Securities |
| Aug 22, 2012 | D | Notice of Exempt Offering of Securities |
| Feb 3, 2012 | D | Notice of Exempt Offering of Securities |